Silicon-mediated isoquinoline alkaloid synthesis: novel route to (±)-xylopinine and (±)-laudanosine

1982 ◽  
pp. 769-770 ◽  
Author(s):  
Seiichi Takano ◽  
Hirotoshi Numata ◽  
Kunio Ogasawara
Keyword(s):  
Isoquinoline Alkaloid ◽  
Alkaloid Synthesis

Regioselectivity in isoquinoline alkaloid synthesis

2010 ◽  
Vol 51 (13) ◽  
pp. 1774-1778 ◽  
Author(s):  
Rodolfo Quevedo ◽  
Edwin Baquero ◽  
Mario Rodriguez
Keyword(s):  
Isoquinoline Alkaloid ◽  
Alkaloid Synthesis

Stereoselective Isoquinoline Alkaloid Synthesis with New Diselenides

Synthesis ◽  
1998 ◽  
Vol 1998 (02) ◽  
pp. 162-166 ◽  
Author(s):  
Thomas Wirth ◽  
Gianfranco Fragale
Keyword(s):  
Isoquinoline Alkaloid ◽  
Alkaloid Synthesis

Studies on intramolecular alkylation. XIV. The preparation of methoxylated cyclohexadienone derivatives from intramolecular diazoketone cyclizations inrelationship to isoquinoline alkaloid synthesis

1981 ◽  
Vol 34 (6) ◽  
pp. 1243 ◽  
Author(s):  
DW Johnson ◽  
LN Mander ◽  
TJ Masters
Keyword(s):  
Trifluoroacetic Acid ◽  
Isoquinoline Alkaloid ◽  
Intramolecular Alkylation ◽  
Alkaloid Synthesis ◽  
Tricyclic Compounds ◽  
Wide Range ◽  
Diazomethyl Ketones

A series of di- and tri-methoxytetrahydronaphthyl diazomethyl ketones (4), (6), (8), (25) and (27) have been prepared and cyclized in trifluoroacetic acid. A wide range of methoxylated cyclohexa- dienone containing tricyclic compounds (12), (15), (17), (18) and (30) were obtained as well as several rearranged derivatives, i.e. (13), (14), (32) and (33).

ChemInform Abstract: Regioselectivity in Isoquinoline Alkaloid Synthesis.

ChemInform ◽  
2010 ◽  
Vol 41 (29) ◽  
pp. no-no
Author(s):  
Rodolfo Quevedo ◽  
Edwin Baquero ◽  
Mario Rodriguez
Keyword(s):  
Isoquinoline Alkaloid ◽  
Alkaloid Synthesis

Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

2020 ◽  
Vol 20 (28) ◽  
pp. 2634-2647
Author(s):  
Dong-Dong Li ◽  
Pan Yu ◽  
Wei Xiao ◽  
Zhen-Zhong Wang ◽  
Lin-Guo Zhao
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Physicochemical Properties ◽  
Isoquinoline Alkaloid ◽  
Hypolipidemic Activity ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lipid Lowering Agent ◽  
Lowering Drug ◽  
Hypolipidemic Drugs

: Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.

Berberine nanoencapsulation attenuates hallmarks of scoplomine induced Alzheimer's-like disease in rats

2020 ◽  
Vol 15 ◽  
Author(s):  
Samar R. Saleh ◽  
Mariam M. Abady ◽  
Mohammed Nofal ◽  
Nashwa W. Yassa ◽  
Mohamed S. Abdel-latif ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Histopathological Examination ◽  
Memory Function ◽  
Amyloid Β ◽  
Active Pharmaceutical Ingredient ◽  
Isoquinoline Alkaloid ◽  
Drug Uptake ◽  
Male Rats ◽  
Morris Water Maze Test ◽  
Neuroprotective Effects

Background: Berberine (BBR), an isoquinoline alkaloid, acts as a multipotent active pharmaceutical ingredient to counteract several types of dementia based on its numerous pharmacological actions including antioxidant, antiinflammatory, cholesterol-lowering effect, and inhibition of Aβ production and AChE. However, BBR suffers from poor absorption, bioavailability and brain drug uptake. The present study is directed for the formulation and characterization of Chitosan BBR-nanoparticles (BBR-NPs) as well as the estimation of its neuroprotective effects against scopolamine induced cognitive impairments. Methods: BBR-NPs were formulated using ionic gelation method and tripolyphosphate was chosen as a cross linker. Nanoparticles size, zeta potential, encapsulation efficiency and releasing profile were estimated. To investigate the neuroprotective effects, adult fifty six Wistar male rats were randomly distributed into: three control groups, received saline, polyethylene glycol or chitosan- NPs respectively; induced group, received scopolamine (2 mg/ kg, i.p.) and three treated groups were orally administrated BBR (50 mg/ kg), BBR- NP (7 mg/ kg) and donepezil (2.25 mg/ kg, as positive control) followed by scopolamine injection after 40 min, daily for 4 weeks. Morris water maze test, oxidative stress parameters, cholinergic and amyloid-β processing intermediates as well as neuroplasticity markers and histopathological examination were assessed. Results: Our results showed that BBR- NPs were better than BBR and donepezil as BBR- NPs were powerful inhibitory ligands toward AChE and Aβ42 formation and significantly down regulated Tau, iNOS and BACE gene expression in rats’ hippocampus. BBR-NPs administration, at 1/6 of BBR therapeutic recommended dose, significantly improved learning and memory function. This could be accredited to the diminution of oxidative stress and amyloid-β toxicity in addition to the improvement of the neuroplasticity markers. Conclusions: The enhancing effect of BBR- NPs could be related to the enhancing of its bioavailability, absorption and brain drug uptake which need more investigation in future work.

Sign in / Sign up

Export Citation Format

Share Document